- Company
- Baxter’s Renal Care Unit spinoff Vantive is launched
- by Whang, byung-woo Feb 6, 2025 05:56am
- With the acquisition process complete for Baxter's Renal Care business, it has newly launched as Vantive, a new company specializing in kidney and life-sustaining organ therapies. The spin-off follows the acquisition of Baxter's Kidney Care business by funds managed by global investment firm The Carlyle Group. As an independent company
- Company
- Imminent launch of the 3rd new CAR-T-cell therapy 'Yescarta'
- by Eo, Yun-Ho Feb 6, 2025 05:56am
- The third CAR-T-cell therapy 'Yescarta' is expected to be commercialized in South Korea. According to industry sources, Gilead Sciences submitted documentation for the approval of the CAR-T-cell therapy, Yescarta (axicabtagene ciloleucel), and the Ministry of Food and Drug Safety (MFDS) is currently conducting the review. Yescarta was
- Policy
- Imlunestrant becomes first reviewed after new drug approval
- by Lee, Hye-Kyung Feb 6, 2025 05:56am
- The first application for a new drug license has been submitted since the fee for drug approval was raised to KRW 410 million. According to industry sources on the 6th, the multinational pharmaceutical company Eli Lilly applied for an marketing authorization for its breast cancer drug 'Inrulio (imlunestrant)' to the Ministry of Food and D
- Policy
- Reimb imminent for switching between atopic dermatitis drugs
- by Lee, Tak-Sun Feb 5, 2025 05:53am
- Switching between atopic dermatitis drugs may be reimbursed soon. This is because the National Health Insurance Service has completed its review through the preliminary drug price reduction system, and all that remains is the National Health Insurance Service's negotiations. As the expected claim amount is not large, the negotiations are e
- InterView
- "High hopes for reimbursed Ilaris…a new treatment option"
- by Whang, byung-woo Feb 5, 2025 05:52am
- The Hereditary Periodic Fever (HPF) syndromes cause not just fever and pain but affect various aspects, such as patient's growth and development, psychological elements. The reimbursement coverage of a new treatment in nine years has increased patient satisfaction." Clinical practices have high hopes for changes to the treatment setting as Il
- Policy
- Low-dose nicergoline continues to be popular
- by Lee, Hye-Kyung Feb 5, 2025 05:52am
- Although it does not indicate the primary treatment of dementia, companies continue to receive approval for their low-dose nicergoline products. . The Ministry of Food and Drug Safety (MFDS) approved Reyon Pharm’s ‘Nicechol Tab. 10mg’ on the 3rd. This is the second approval this year, following the approval of the ‘Neurogoline Tab. 10mg’
- Company
- 1st to exceed KRW 1T sales…Pfizer's ESG initiatives
- by Whang, byung-woo Feb 5, 2025 05:52am
- Pfizer Korea, the first to exceed KRW 1 trillion in sales from COVID-19 vaccine·treatments, continues strengthening its sustainable business management based on the ESG initiative. After recording KRW 3 trillion in 2022 during the COVID-19 pandemic, Pifzer Korea's sales robustly decreased. However, despite unusual circumstances, the i
- Company
- Multiple sclerosis drug Ocrevus may soon be reimbursed
- by Eo, Yun-Ho Feb 5, 2025 05:52am
- The new multiple sclerosis drug Ocrevus is expected to be listed for reimbursement in Kore. According to industry sources, Roche Korea has completed negotiations with the National Health Insurance Service on the drug price of Ocrevus (ocrelizumab) for relapsing multiple sclerosis (MS). As a result, the drug is expected to be reimbursed
- Company
- Hepatitis B drug market remakes ₩300B after 6 years
- by Kim, Jin-Gu Feb 4, 2025 05:55am
- The outpatient prescription market for hepatitis B drugs expanded again last year to exceed KRW 300 billion. This is the first time the market has exceeded the mark in 6 years since 2018. Gilead Sciences’ Vemlidy drove the market growth with a 15% increase in sales from KRW 61.9 billion to KRW 71.3 billion in 1 year, while the combined pres
- Company
- 'Tibsovo' reapplies for bile duct cancer indication reimb
- by Eo, Yun-Ho Feb 4, 2025 05:55am
- 'Tibsovo,' which is indicated for the treatment of bile duct cancer (cholangiocarcinoma) and acute myeloid leukemia (AML), reapplies for obtaining insurance reimbursement. According to industry sources, Servier Korea has submitted a reimbursement application for cholangiocarcinoma indication of Tibsovo (ivosidenib), a drug targeting the i
